Sono-Photodynamic Therapy with Photolon for Recurrence Glioblastoma Grade IV: Case Report and Review of Experimental Studies
Pages 62-66
D.A. Tzerkovsky, Yu.P. Istomin, T.P. Artemieva, Yu.N. Grachev and F.F. Borichevsky

DOI: http://dx.doi.org//10.6000/1927-7229.2016.05.02.3
Published: 05 May 2016

Abstract: Aim: to view the first clinical testing for intraoperative sono-photodynamic therapy (iSPDT) with a photosensitizer (PS) photolon for patient with recurrent glioblastoma grade IV.

Materials and Methods: in patient with recurrent glioblastoma with Karnofsky score 80, a single intravenous injection of chlorin-based PS photolon at a dose of 2 mg/kg was administered 0.5 hour before tumor resection. The resection cavity were sonicated («Phyaction USTH 91», 1.04 MHz, 1.0 W/cm²) and photoirradiated («PDT DIODE LASER», λ=660±5 nm, 50 J/cm², 100 mW/cm²). Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0). Immediate results were evaluated based on data magnetic resonance imaging (MRI) after 3 and 6 months after treatment.

Results: no adverse events directly attributable to iSPDT occurred in patient. According to the MRI control in terms of 3 and 6 months revealed tumor stabilization. The follow-up after diagnosis verification was 23 months, post-iSPDT follow-up – 16.5 month and recurrence-free period – 6 months.

Conclusion: iSPDT with photolon may be considered as a potentially effective and sufficiently safe option for adjuvant management of reccurent glioblastoma.